<html>

<head>
<meta HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=windows-1252">
<meta NAME="GENERATOR" CONTENT="Microsoft FrontPage 3.0">
<title>WARNING: SEVERE, LIFE-THREATENING HUMAN BIRTH DEFECTS</title>

</head>

<body bgcolor="#FFFFFF">

<table BORDER="1" CELLSPACING="1" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="100%">
  <tr>
    <td VALIGN="TOP" width="928"><b>WARNING: SEVERE, LIFE-THREATENING HUMAN BIRTH DEFECTS<p>IF
    THALIDOMIDE IS TAKEN DURING PREGNANCY, IT CAN CAUSE SEVERE BIRTH DEFECTS OR DEATH TO AN
    UNBORN BABY. THALIDOMIDE SHOULD NEVER BE USED BY WOMEN WHO ARE PREGNANT OR WHO COULD
    BECOME PREGNANT WHILE TAKING THE DRUG. EVEN A SINGLE DOSE [1 CAPSULE (50 mg)] TAKEN BY A
    PREGNANT WOMAN DURING HER PREGNANCY CAN CAUSE SEVERE BIRTH DEFECTS.</p>
    <p>BECAUSE OF THIS TOXICITY AND IN AN EFFORT TO MAKE THE CHANCE OF FETAL EXPOSURE TO
    THALOMID AS NEGLIGIBLE AS POSSIBLE, THALOMID IS APPROVED FOR MARKETING ONLY UNDER A
    SPECIAL RESTRICTED DISTRIBUTION PROGRAM APPROVED BY THE FOOD AND DRUG ADMINISTRATION. THIS
    PROGRAM IS CALLED THE &quot;SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY
    (S.T.E.P.S.)&quot;. </p>
    <p>UNDER THIS RESTRICTED DISTRIBUTION PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED
    WITH THE PROGRAM ARE ALLOWED TO PRESCRIBE AND DISPENSE THE PRODUCT. IN ADDITION, PATIENTS
    MUST BE ADVISED OF, AGREE TO, AND COMPLY WITH THE REQUIREMENTS OF THE S.T.E.P.S. PROGRAM
    IN ORDER TO RECEIVE PRODUCT. </p>
    <p>PLEASE SEE THE FOLLOWING BOXED WARNINGS CONTAINING SPECIAL INFORMATION FOR PRESCRIBERS,
    FEMALE PATIENTS, AND MALE PATIENTS ABOUT THIS RESTRICTED DISTRIBUTION PROGRAM.</b></td>
  </tr>
</table>

<p>&nbsp;</p>

<table BORDER="1" CELLSPACING="1" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="100%">
  <tr>
    <td VALIGN="TOP"><u><b>&nbsp;<p ALIGN="CENTER">PRESCRIBERS</p>
    </b></u><p>THALOMID<sup>TM</sup> (thalidomide) may be prescribed only by licensed
    prescribers who are registered in the <i>S.T.E.P.S.</i> program and understand the risk of
    teratogenicity if thalidomide is used during pregnancy.</p>
    <p>Major human fetal abnormalities related to thalidomide administration during pregnancy
    have been documented: amelia (absence of limbs), phocomelia (short limbs), hypoplasticity
    of the bones, absence of bones, external ear abnormalities (including anotia, micro pinna,
    small or absent external auditory canals), facial palsy, eye abnormalities (anophthalmos,
    microphthalmos), and congenital heart defects. Alimentary tract, urinary tract, and
    genital malformations have also been documented.<sup>1</sup> Mortality at or shortly after
    birth has been reported at about 40%.<sup>2</p>
    </sup><p>Effective contraception (see <b>CONTRAINDICATIONS</b>) must be used for at least
    1 month before beginning thalidomide therapy, during thalidomide therapy, and for 1 month
    following discontinuation of thalidomide therapy. Reliable contraception is indicated even
    where there has been a history of infertility, unless due to hysterectomy or because the
    patient has been post-menopausal for at least 24 months. Two reliable forms of
    contraception must be used simultaneously unless continuous abstinence from reproductive
    heterosexual sexual intercourse is the chosen method. Women of childbearing potential
    should be referred to a qualified provider of contraceptive methods, if needed. <font
    FACE="HTELFNT">Sexually mature women who have not undergone a hysterectomy or who have not
    been post-menopausal for at least 24 consecutive months (i.e., who have had menses at some
    time in the preceding 24 consecutive months) are considered to be women of child-bearing
    potential.</p>
    </font><b><p>Before starting treatment</b>, women of childbearing potential should have a
    pregnancy test (sensitivity of at least 50 mIU/mL). The test should be performed within
    the 24 hours prior to beginning therapy. A prescription for thalidomide for a woman of
    childbearing potential must not be issued by the prescriber until a written report of a
    negative pregnancy test has been obtained by the prescriber. </p>
    <b><p>Once treatment has started</b>, pregnancy testing should occur weekly during the
    first month of use, then monthly thereafter in women with regular menstrual cycles. If
    menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks.
    Pregnancy testing and counseling should be performed if a patient misses her period or if
    there is any abnormality in menstrual bleeding.</p>
    <p>If pregnancy does occur during thalidomide treatment, thalidomide must be discontinued
    immediately. </p>
    <p>Any suspected fetal exposure to THALOMID (thalidomide) must be reported immediately to
    the FDA <i>via</i> the MedWATCH number at 1-800-FDA-1088 and also to Celgene Corporation.
    The patient should be referred to an obstetrician/gynecologist experienced in reproductive
    toxicity for further evaluation and counseling.</p>
    <p>&nbsp;</p>
    <p>&nbsp;</td>
  </tr>
</table>

<p>&nbsp;</p>
<font FACE="HTELFNT"><u><b>

<p>&nbsp;</p>
</b></u></font>

<table BORDER="1" CELLSPACING="1" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="100%">
  <tr>
    <td VALIGN="TOP"><font FACE="HTELFNT"><u><b>&nbsp;<p ALIGN="CENTER">FEMALE PATIENTS</b></u></font></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font FACE="HTELFNT">Thalidomide is contraindicated in WOMEN of
    childbearing potential unless alternative therapies are considered inappropriate AND the
    patient MEETS ALL OF THE FOLLOWING CONDITIONS (i.e., she is essentially unable to become
    pregnant while on thalidomide therapy):<ul>
      <li>she understands and can reliably carry out instructions.</li>
    </ul>
    <ul>
      <li>she is capable of complying with the mandatory contraceptive measures, pregnancy
        testing, patient registration, and patient survey as described in the System for
        Thalidomide Education and Prescribing Safety (<i>S.T.E.P.S.</i>) program.</li>
    </ul>
    <ul>
      <li>she has received both oral and written warnings of the hazards of taking thalidomide
        during pregnancy and of exposing a fetus to the drug.</li>
    </ul>
    <ul>
      <li>she has received both oral and written warnings of the risk of possible contraception
        failure and of the need to use two reliable forms of contraception simultaneously <i>(</i>see
        <b>CONTRAINDICATIONS</b>), unless continuous abstinence from reproductive heterosexual
        intercourse is the chosen method. (Sexually mature women who have not undergone a
        hysterectomy or who have not been post-menopausal for at least 24 consecutive months
        (i.e., who have had menses at some time in the preceding 24 consecutive months) are
        considered to be women of child-bearing potential.).</li>
    </ul>
    <ul>
      <li>she acknowledges, in writing, her understanding of these warnings and of the need for
        using two reliable methods of contraception for one month prior to starting thalidomide
        therapy, during thalidomide therapy, and for one month after stopping thalidomide therapy.</li>
    </ul>
    <ul>
      <li>she has had a negative pregnancy test with a sensitivity of at least 50 mIU/mL, within
        the 24 hours prior to beginning therapy. (See <b>PRECAUTIONS, CONTRAINDICATIONS.</b>)</li>
    </ul>
    <ul>
      <li>if the patient is between 12 and 18 years of age, her parent or legal guardian must have
        read this material and agreed to ensure compliance with the above.</font></li>
    </ul>
    </td>
  </tr>
</table>
<font FACE="HTELFNT">

<p>&nbsp;</p>

<p>&nbsp;</p>
</font>

<table BORDER="1" CELLSPACING="1" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="100%">
  <tr>
    <td VALIGN="TOP"><u><b><font FACE="HTELFNT">&nbsp;<p ALIGN="CENTER">MALE PATIENTS</font></b></u></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font FACE="HTELFNT">Thalidomide is contraindicated in sexually mature
    MALES unless the PATIENT MEETS ALL OF THE FOLLOWING CONDITIONS:<ul>
      <li>he understands and can reliably carry out instructions.</li>
    </ul>
    <ul>
      <li>he is capable of complying with the mandatory contraceptive measures that are
        appropriate for men, patient registration, and patient survey as described in the <i>S.T.E.P.S.</i>
        program.</li>
    </ul>
    <ul>
      <li>he has received both oral and written warnings of the hazards of taking thalidomide and
        exposing a fetus to the drug.</li>
    </ul>
    <ul>
      <li>he has received both oral and written warnings of the risk of possible contraception
        failure and of the need to use barrier contraception when having sexual intercourse with
        women of childbearing potential, even if he has undergone successful vasectomy.</li>
    </ul>
    <ul>
      <li>he acknowledges, in writing, his understanding of these warnings and of the need for
        using barrier contraception (latex condom), even if he has undergone successful vasectomy,
        when having sexual intercourse with women of childbearing potential. Sexually mature women
        who have not undergone a hysterectomy or who have not been post-menopausal for at least 24
        consecutive months (i.e., who have had menses at some time in the preceding 24 consecutive
        months) are considered to be women of child-bearing potential.</li>
    </ul>
    <ul>
      <li>if the patient is between 12 and 18 years of age, his parent or legal guardian must have
        read this material and agreed to ensure compliance with the above.</font></li>
    </ul>
    </td>
  </tr>
</table>
<font FACE="HTELFNT">

<p>&nbsp;</p>
<b>

<p>CLINICAL PHARMACOLOGY</p>

<p>Mechanism of Action</p>
</b>

<p>Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully
characterized. In patients with erythema nodosum leprosum (ENL) the mechanism of action is
not fully understood.</p>

<p>Available data from <i>in vitro</i> studies and preliminary clinical trials suggest
that the immunologic effects of this compound can vary substantially under different
conditions, but, may be related to suppression of excessive tumor necrosis factor-alpha
(TNF-</font><font FACE="Symbol">a</font><font FACE="HTELFNT">) production and
down-modulation of selected cell surface adhesion molecules involved in leukocyte
migration<sup>3,4,5,6</sup>. For example, administration of thalidomide has been reported
to decrease circulating levels of TNF-</font><font FACE="Symbol">a</font><font
FACE="HTELFNT"> in patients with ENL<sup>3</sup>, however, it has also been shown to
increase plasma TNF-</font><font FACE="Symbol">a</font><font FACE="HTELFNT"> levels in
HIV-seropositive patients<sup>7</sup>.</p>
<b>

<p>Pharmacokinetics and Drug Metabolism</p>
<i>

<p>Absorption</p>
</i></b>

<p>The absolute bioavailability of thalidomide from THALOMID capsules has not yet been
characterized in human subjects due to its poor aqueous solubility. In studies of both
healthy volunteers and subjects with Hansen</font><font face="WP TypographicSymbols">'</font><font
FACE="HTELFNT">s disease, the mean time to peak plasma concentrations (T<sub>max</sub>) of
THALOMID ranged from 2.9 to 5.7 hours indicating that THALOMID is slowly absorbed from the
gastrointestinal tract. While the extent of absorption (as measured by area under the
curve [AUC]) is proportional to dose in healthy subjects, the observed peak concentration
(C<sub>max</sub>) increased in a less than proportional manner (see Table 1 below). This
lack of C<sub>max</sub> dose proportionality, coupled with the observed increase in T<sub>max</sub>
values, suggests that the poor solubility of thalidomide in aqueous media may be hindering
the rate of absorption.</p>
<b>

<p ALIGN="CENTER">Table 1</p>

<p ALIGN="CENTER">Pharmacokinetic Parameter Values for THALOMID (thalidomide)</p>

<p ALIGN="CENTER">Mean (%CV)</p>
</b></font>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="7" WIDTH="676">
  <tr>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Population/</p>
    <p ALIGN="CENTER">Single Dose</b></font></td>
    <td WIDTH="23%" VALIGN="TOP"><b><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">AUC<sub>0-</font><font
    FACE="WP MathA" SIZE="2">4</p>
    </font></sub><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">(</font><font FACE="Symbol"
    SIZE="2">m</font><font FACE="HTELFNT" SIZE="2">g</font><font FACE="WP Greek Century"
    SIZE="2">q</font><font FACE="HTELFNT" SIZE="2">hr/mL)</font></b></td>
    <td WIDTH="17%" VALIGN="TOP"><b><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">C<sub>max</p>
    </sub><p ALIGN="CENTER">(</font><font FACE="Symbol" SIZE="2">m</font><font FACE="HTELFNT"
    SIZE="2">g/mL)</font></b></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">T<sub>max</p>
    </sub><p ALIGN="CENTER">(hrs)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Half-life</p>
    <p ALIGN="CENTER">(hrs)</b></font></td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="7" WIDTH="677">
  <tr>
    <td VALIGN="TOP"><font FACE="HTELFNT" SIZE="2">Healthy Subjects (n=14)</font></td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="7" WIDTH="676">
  <tr>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">50 mg</font></td>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">4.9 (16%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">0.62 (52%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">2.9 (66%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">5.52 (37%)</font></td>
  </tr>
  <tr>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">200 mg</font></td>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">18.9 (17%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">1.76 (30%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">3.5 (57%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">5.53 (25%)</font></td>
  </tr>
  <tr>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">400 mg</font></td>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">36.4 (26%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">2.82 (28%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">4.3 (37%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">7.29 (36%)</font></td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="7" WIDTH="677">
  <tr>
    <td VALIGN="TOP"><font FACE="HTELFNT" SIZE="2">Patients with Hansen</font><font
    face="WP TypographicSymbols" size="2">'</font><font FACE="HTELFNT" SIZE="2">s Disease
    (n=6)</font></td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="7" WIDTH="676">
  <tr>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">400 mg</font></td>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">46.4 (44.1%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">3.44 (52.6%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">5.7 (27%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">6.86 (17%)</font></td>
  </tr>
</table>
<font FACE="HTELFNT">

<p>Co-administration of THALOMID with a high fat meal causes minor (&lt;10%) changes in
the observed AUC and C<sub>max</sub> values: however, it causes an increase in T<sub>max</sub>
to approximately 6 hours.</p>
<b><i>

<p ALIGN="JUSTIFY">Distribution</p>
</i>

<p ALIGN="JUSTIFY">It is not known whether thalidomide is present in the ejaculate of
males.</p>
</b>

<p ALIGN="JUSTIFY">The extent of plasma protein binding of thalidomide is unknown. </p>
<i><b>

<p ALIGN="JUSTIFY">Metabolism</p>
</b></i>

<p ALIGN="JUSTIFY">At the present time, the exact metabolic route and fate of thalidomide
is not known in humans. Thalidomide itself does not appear to be hepatically metabolized
to any large extent, but appears to undergo non-enzymatic hydrolysis in plasma to multiple
metabolites. In a repeat dose study in which THALOMID (thalidomide) 200 mg was
administered to 10 healthy females for 18 days, thalidomide displayed similar
pharmacokinetic profiles on the first and last day of dosing. This suggests that
thalidomide does not induce or inhibit its own metabolism. </p>
<i><b>

<p ALIGN="JUSTIFY">Elimination</p>
</b></i>

<p ALIGN="JUSTIFY">As indicated in Table 1 (above) the mean half-life of elimination
ranges from approximately 5 to 7 hours following a single dose and is not altered upon
multiple dosing. As noted in the metabolism subsection, the precise metabolic fate and
route of elimination of thalidomide in humans is not known at this time. Thalidomide
itself has a renal clearance of 1.15 mL/minute with less than 0.7% of the dose excreted in
the urine as unchanged drug. Following a single dose, urinary levels of thalidomide were
undetectable 48 hrs after dosing. Although thalidomide is thought to be hydrolyzed to a
number of metabolites<sup>8</sup>, only a very small amount (0.02% of the administered
dose) of 4-OH-thalidomide was identified in the urine of subjects 12 to 24 hours after
dosing. </p>
<i><b>

<p ALIGN="JUSTIFY">Pharmacokinetic Data in Special Populations</p>
</b>

<p ALIGN="JUSTIFY">HIV-seropositive Subjects:</i> There is no apparent significant
difference in measured pharmacokinetic parameter values between healthy human subjects and
HIV-seropositive subjects following single dose administration of THALOMID (thalidomide)
capsules.</p>
<i>

<p ALIGN="JUSTIFY">Patients with Hansen</font><font face="WP TypographicSymbols">'</font><font
FACE="HTELFNT">s Disease:</i> Analysis of data from a small study in Hansen</font><font
face="WP TypographicSymbols">'</font><font FACE="HTELFNT">s patients suggests that these
patients, relative to healthy subjects, may have an increased bioavailability of THALOMID.
The increase is reflected both in an increased area under the curve and in increased peak
plasma levels. The clinical significance of this increase is unknown.</p>
<i>

<p ALIGN="JUSTIFY">Patients with Renal Insufficiency:</i> The pharmacokinetics of
thalidomide in patients with renal dysfunction have not been determined.</p>
<i>

<p ALIGN="JUSTIFY">Patients with Hepatic Disease:</i> The pharmacokinetics of thalidomide
in patients with hepatic impairment have not been determined.</p>
<i>

<p ALIGN="JUSTIFY">Age:</i> Analysis of the data from pharmacokinetic studies in healthy
volunteers and patients with Hansen</font><font face="WP TypographicSymbols">'</font><font
FACE="HTELFNT">s disease ranging in age from 20 to 69 years does not reveal any
age-related changes.</p>
<i>

<p ALIGN="JUSTIFY">Pediatric: </i>No pharmacokinetic data are available in subjects below
the age of 18 years.</p>
<i>

<p ALIGN="JUSTIFY">Gender:</i> While a comparative trial of the effects of gender on
thalidomide pharmacokinetics has not been conducted, examination of the data for
thalidomide does not reveal any significant gender differences in pharmacokinetic
parameter values.</p>
<i>

<p ALIGN="JUSTIFY">Race:</i> Pharmacokinetic differences due to race have not been
studied. </p>
<i><b>

<p ALIGN="JUSTIFY">Clinical Studies</p>
</b></i>

<p ALIGN="JUSTIFY">The primary data demonstrating the efficacy of thalidomide in the
treatment of the cutaneous manifestations of moderate to severe ENL are derived from the
published medical literature and from a retrospective study of 102 patients treated by the
U.S. Public Health Service.</p>

<p ALIGN="JUSTIFY">Two double blind, randomized, controlled trials reported the
dermatologic response to a 7 day course of 100 mg thalidomide (four times daily) or
control. Dosage was lower for patients under 50 kg in weight.</p>
<b>

<p ALIGN="JUSTIFY">Table 2</p>

<p ALIGN="CENTER">Double Blind, Controlled Clinical Trials of Thalidomide in Patients with
ENL:</p>

<p ALIGN="CENTER">Cutaneous Response</p>
</b></font>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="689">
  <tr>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Reference</b></font></td>
    <td WIDTH="22%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">No. of
    Patients</b></font></td>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">No.
    Treatment Courses*</b></font></td>
    <td WIDTH="31%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Percent
    Responding**</b></font></td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="689">
  <tr>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2">Iyer <i>et al.</i><sup>9</sup><p>Bull
    World Health Organization 1971; 45:719</font></td>
    <td WIDTH="22%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">92</font></td>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2">&nbsp;<p ALIGN="CENTER">204</font></td>
    <td WIDTH="16%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">Thalidomide</p>
    <p ALIGN="CENTER">75%</font></td>
    <td WIDTH="14%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">Aspirin</p>
    <p ALIGN="CENTER">25%</font></td>
  </tr>
  <tr>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2">Sheskin<i> et al.</i><sup>10</sup><i>
    </i><p>Int J Lep<i> </i>1969; 37:135</font></td>
    <td WIDTH="22%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">52</font></td>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">173</font></td>
    <td WIDTH="16%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">Thalidomide</p>
    <p ALIGN="CENTER">66%</font></td>
    <td WIDTH="14%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">Placebo</p>
    <p ALIGN="CENTER">10%</font></td>
  </tr>
</table>
<font FACE="HTELFNT">

<p ALIGN="CENTER">* In patients with cutaneous lesions</p>

<p ALIGN="CENTER">** Iyer: Complete response or lesions absent</p>

<p ALIGN="CENTER">** Sheskin: Complete Improvement + &quot;striking&quot; improvement
(i.e., &gt;50% improvement) </p>

<p>Waters<sup>11</sup> reported the results of two studies, both double blind, randomized,
placebo controlled, crossover trials in a total of 10 hospitalized, steroid-dependent
patients with chronic ENL treated with 100 mg thalidomide or placebo (three times daily).
All patients also received dapsone. The primary endpoint was reduction in weekly steroid
dosage.</p>
<b>

<p ALIGN="CENTER">Table 3</p>

<p ALIGN="CENTER">Double Blind, Controlled Trial of Thalidomide in Patients with ENL:</p>

<p ALIGN="CENTER">Reduction in Steroid Dosage</p>
</b></font>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="689">
  <tr>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Reference</b></font></td>
    <td WIDTH="22%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Duration
    of</b></font></td>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">No. of
    Patients</b></font></td>
    <td WIDTH="31%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Number
    Responding</b></font></td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="689">
  <tr>
    <td WIDTH="23%" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="22%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Treatment</b></font></td>
    <td WIDTH="24%" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="16%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Thalidomide</b></font></td>
    <td WIDTH="14%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><b><p ALIGN="CENTER">Placebo</b></font></td>
  </tr>
  <tr>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2">Waters<sup>11</sup></font></td>
    <td WIDTH="22%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">4 weeks</font></td>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">9</font></td>
    <td WIDTH="16%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">4/5</font></td>
    <td WIDTH="14%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">0/4</font></td>
  </tr>
  <tr>
    <td WIDTH="23%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2">Lep Rev 1971; 42:26</font></td>
    <td WIDTH="22%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">6 weeks
    (crossover)</font></td>
    <td WIDTH="24%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">8</font></td>
    <td WIDTH="16%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">8/8</font></td>
    <td WIDTH="14%" VALIGN="TOP"><font FACE="HTELFNT" SIZE="2"><p ALIGN="CENTER">1/8</font></td>
  </tr>
</table>
<font FACE="HTELFNT">

<p>Data on the efficacy of thalidomide in prevention of ENL relapse were derived from a
retrospective evaluation of 102 patients treated under the auspices of the U.S. Public
Health Service. A subset of patients with ENL controlled on thalidomide demonstrated
repeated relapse upon drug withdrawal and remission with reinstitution of therapy.</p>

<p>Twenty U.S. patients between the ages of 11 and 17 years were treated wtih thalidomide,
generally at 100 mg daily. Response rates and safety profiles were similar to that
observed in the adult population.</p>

<p>Thirty-two other published studies containing over 1600 patients consistently report
generally successful treatment of the cutaneous manifestations of moderate to severe ENL
with thalidomide.</p>
<b>

<p>&nbsp;</p>

<p>INDICATIONS AND USAGE</p>
</b>

<p>THALOMID (thalidomide) is indicated for the acute treatment of the cutaneous
manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID
(thalidomide) is not indicated as monotherapy for such ENL treatment in the presence of
moderate to severe neuritis. </p>

<p>THALOMID (thalidomide) is also indicated as<b> </b>maintenance therapy for prevention
and suppression of the cutaneous manifestations of ENL recurrence.</p>
<b>

<p>&nbsp;</p>

<p>CONTRAINDICATIONS (See BOXED WARNINGS.)</p>

<p>Pregnancy: Category X</b> </p>

<p>Due to its known human teratogenicity, even following a single dose, thalidomide is
contraindicated in pregnant women and women capable of becoming pregnant. (See <b>BOXED
WARNINGS.</b>) When there is no alternative treatment, women of childbearing potential may
be treated with thalidomide provided adequate precautions are taken to avoid pregnancy.
Women must commit either to abstain continuously from heterosexual sexual intercourse or
to use two methods of reliable birth control, including at least one highly effective
method (<i>e.g.</i>, IUD, hormonal contraception, tubal ligation, or partner</font><font
face="WP TypographicSymbols">'</font><font FACE="HTELFNT">s vasectomy) and one additional
effective method (<i>e.g.</i>, latex condom, diaphragm, or cervical cap), beginning 4
weeks prior to initiating treatment with thalidomide, during therapy with thalidomide, and
continuing for 4 weeks following discontinuation of thalidomide therapy. If hormonal or
IUD contraception is medically contraindicated (see also <b>PRECAUTIONS:</b> <b>DRUG
INTERACTIONS</b>), two other effective or highly effective methods may be used.</p>

<p>Women of childbearing potential being treated with thalidomide should have pregnancy
testing (sensitivity of at least 50 mIU/mL). The test should be performed within the 24
hours before beginning thalidomide therapy and then weekly during the first month of
thalidomide therapy, then monthly thereafter in women with regular menstrual cycles or
every 2 weeks in women with irregular menstrual cycles. Pregnancy testing and counseling
should be performed if a patient misses her period or if there is any abnormality in
menstrual bleeding. If pregnancy occurs during thalidomide treatment, thalidomide must be
immediately discontinued. Under these conditions, the patient should be referred to an
obstetrician / gynecologist experienced in reproductive toxicity for further evaluation
and counseling.</p>

<p>THALOMID (thalidomide) is contraindicated in patients who have demonstrated
hypersensitivity to the drug and its components.</p>
<b>

<p>&nbsp;</p>

<p>WARNINGS (See BOXED WARNINGS.)</p>

<p>Birth defects:</p>
</b>

<p>Thalidomide can cause severe birth defects in humans. (See <b>BOXED WARNING</b> and <b>CONTRAINDICATIONS.</b>)
Patients should be instructed to take thalidomide only as prescribed and not to share
their thalidomide with anyone else. Because it is not known whether or not thalidomide is
present in the ejaculate of males receiving the drug, males receiving thalidomide must
always use a latex condom when engaging in sexual activity with women of childbearing
potential.</p>
<b>

<p>Drowsiness and somnolence:</p>
</b>

<p>Thalidomide frequently causes drowsiness and somnolence. Patients should be instructed
to avoid situations where drowsiness may be a problem and not to take other medications
that may cause drowsiness without adequate medical advice. Patients should be advised as
to the possible impairment of mental and/or physical abilities required for the
performance of hazardous tasks, such as driving a car or operating other complex or
dangerous machinery.</p>
<b>

<p>Peripheral neuropathy:</p>
</b></font>

<p>Thalidomide is known to cause nerve damage that may be permanent. Peripheral neuropathy
is a common, potentially severe, side effect of treatment with thalidomide that may be
irreversible. Peripheral neuropathy generally occurs following chronic use over a period
of months, however, reports following relatively short term use also exist. The
correlation with cumulative dose is unclear. Symptoms may occur some time after
thalidomide treatment has been stopped and may resolve slowly or not at all. Few reports
of neuropathy have arisen in the treatment of ENL despite long-term thalidomide treatment.
However, the inability clinically to differentiate thalidomide neuropathy from the
neuropathy often seen in Hansen's disease makes it difficult to determine accurately the
incidence of thalidomide-related neuropathy in ENL patients treated with thalidomide.</p>

<p>Patients should be examined at monthly intervals for the first 3 months of thalidomide
therapy to enable the clinician to detect early signs of neuropathy, which include
numbness, tingling or pain in the hands and feet. Patients should be evaluated
periodically thereafter during treatment. Patients should be regularly counseled,
questioned, and evaluated for signs or symptoms of peripheral neuropathy. Consideration
should be given to electrophysiological testing, consisting of measurement of sensory
nerve action potential (SNAP) amplitudes at baseline and thereafter every 6 months in an
effort to detect asymptomatic neuropathy. If symptoms of drug-induced neuropathy develop,
thalidomide should be discontinued immediately to limit further damage, if clinically
appropriate. Usually, treatment with thalidomide should only be reinitiated if the
neuropathy returns to baseline status. Medications known to be associated with neuropathy
should be used with caution in patients receiving thalidomide.</p>

<p>&nbsp;</p>
<font FACE="HTELFNT"><b>

<p>Dizziness and orthostatic hypotension:</p>
</b>

<p>Patients should also be advised that thalidomide may cause dizziness and orthostatic
hypotension and that, therefore, they should sit upright for a few minutes prior to
standing up from a recumbent position. </p>
</font><b>

<p>Neutropenia:</p>
</b>

<p>Decreased white blood cell counts, including neutropenia, have been reported in
association with the clinical use of thalidomide. Treatment should not be initiated with
an absolute neutrophil count (ANC) of &lt;750/mm<sup>3</sup>. White blood cell count and
differential should be monitored on an on-going basis, especially in patients who may be
more prone to neutropenia, such as patients who are HIV-seropositive. If ANC decreases to
below 750/mm<sup>3</sup> while on treatment, the patient<font face="WP TypographicSymbols">'</font>s
medication regimen should be re-evaluated and, if the neutropenia persists, consideration
should be given to withholding thalidomide if clinically appropriate. </p>
<b>

<p>Increased HIV-Viral Load:</p>
</b>

<p>In a randomized, placebo controlled trial of thalidomide in an HIV-seropositive patient
population, plasma HIV RNA levels were found to increase (median change = 0.42 log<sub>10</sub>
copies HIV RNA/mL, p = 0.04 compared to placebo)<sup>7</sup>. A similar trend was observed
in a second, unpublished study conducted in patients who were HIV-seropostive<sup>12</sup>.
The clinical significance of this increase is unknown. Both studies were conducted prior
to availability of highly active antiretroviral therapy. Until the clinical significance
of this finding is further understood, in HIV-seropositive patients, viral load should be
measured after the first and third months of treatment and every 3 months thereafter.</p>

<p>&nbsp;</p>
<b>

<p>PRECAUTIONS</p>

<p>Hypersensitivity:</p>
</b>

<p>Hypersensitivity to THALOMID (thalidomide) has been reported. Signs and symptoms have
included the occurrence of erythematous macular rash, possibly associated with fever,
tachycardia, and hypotension, and if severe, may necessitate interruption of therapy. If
the reaction recurs when dosing is resumed, THALOMID (thalidomide) should be discontinued.</p>
<b>

<p>Bradycardia:</p>
</b>

<p>Bradycardia in association with thalidomide use has been reported. At present there
have been no reports of bradycardia requiring medical or other intervention. The clinical
significance and underlying etiology of the bradycardia noted in some thalidomide-treated
patients are present unknown. </p>

<p>&nbsp;</p>
<b>

<p>Information for Patients (See BOXED WARNINGS.)</p>
</b>

<p>Patient should be instructed about the potential teratogenicity of thalidomide and the
precautions that must be taken to preclude fetal exposure as per the S.T.E.P.S. program
and boxed warnings in this package insert. Patients should be instructed to take
thalidomide only as prescribed in compliance with all of the provisions of the S.T.E.P.S.
Restricted Distribution Program.</p>

<p>Patients should be instructed not to share medication with anyone else.</p>

<p>Patients should be instructed that thalidomide frequently causes drowsiness and
somnolence. Patients should be instructed to avoid situations where drowsiness may be a
problem and not to take other medications that may cause drowsiness without adequate
medical advice. Patients should be advised as to the possible impairment of mental and/or
physical abilities required for the performance of hazardous tasks, such as driving a car
or operating other complex machinery. Patients should be instructed that thalidomide may
potentiate the somnolence caused by alcohol.</p>

<p>Patients should be instructed that thalidomide can cause peripheral neuropathies that
may be initially signaled by numbness, tingling, or pain or a burning sensation in the
feet or hands. Patients should be instructed to report such occurrences to their
prescriber immediately. </p>

<p>Patients should also be instructed that thalidomide may cause dizziness and orthostatic
hypotension and that, therefore, they should sit upright for a few minutes prior to
standing up from a recumbent position.</p>

<p>Patients should be instructed that they are not permitted to donate blood while taking
thalidomide. In addition, male patients should be instructed that they are not permitted
to donate sperm while taking thalidomide.</p>
<b>

<p>Laboratory Tests</p>
<i>

<p>Pregnancy Testing:</i></b> (<b>See BOXED WARNINGS.) </b>Women of childbearing potential
should have pregnancy testing performed (sensitivity of at least 50 mIU/mL). The test
should be performed within the 24 hours prior to beginning thalidomide therapy and then
weekly during the first month of use, then monthly thereafter in women with regular
menstrual cycles or every 2 weeks in women with irregular menstrual cycles. Pregnancy
testing should also be performed if a patient misses her period or if there is any
abnormality in menstrual bleeding.</p>
<i>

<p>Neutropenia: </i><b>(See WARNINGS.)</p>
</b><i>

<p>HIV Viral Load: </i><b>(See WARNINGS.)</p>
</b>

<p>&nbsp;</p>
<b>

<p>Drug Interactions</p>
</b>

<p>Thalidomide has been reported to enhance the sedative activity of barbiturates,
alcohol, chlorpromazine, and reserpine.</p>
<i><b>

<p>Peripheral Neuropathy:</b></i> Medications known to be associated with peripheral
neuropathy should be used with caution in patients receiving thalidomide.</p>
<i><b>

<p>Oral Contraceptives:</b></i> In 10 healthy women, the pharmacokinetic profiles of
norethindrone and ethinyl estradiol following administration of a single dose containing
1.0 mg of norethindrone acetate and 75 <font FACE="Symbol">m</font>g of ethinyl estradiol
were studied. The results were similar with and without coadministration of thalidomide
200 mg/day to steady-state levels.</p>
<b>

<p>Important Non-Thalidomide Drug Interactions</p>
<i>

<p>Drugs That Interfere with Hormonal Contraceptives:</i></b> Concomitant use of
HIV-protease inhibitors, griseofulvin, rifampin, rifabutin, phenytoin, or carbamazepine
with hormonal contraceptive agents, may reduce the effectiveness of the contraception.
Therefore, women requiring treatment with one or more of these drugs must use two OTHER
effective or highly effective methods of contraception or abstain from reproductive
heterosexual sexual intercourse.</p>
<b>

<p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p>
</b>

<p>Long-term carcinogenicity tests have not been conducted using thalidomide. Thalidomide
gave no evidence of mutagenic effects when assayed in <i>in vitro</i> bacterial (<i>Salmonella
typhimurium </i>and<i> Escherichia coli</i>; Ames mutagenicity test), <i>in vitro</i>
mammalian (AS52 Chinese hamster ovary cells; AS52/XPRT mammalian cell forward gene
mutation assay) and <i>in vivo</i> mammalian (CD-1 mice; <i>in vivo</i> micronucleus test)
test systems. </p>

<p>Animal studies to characterize the effects of thalidomide on fertility have not been
conducted.</p>
<b>

<p>Pregnancy</p>
<i>

<p>Pregnancy Category X:</i> See BOXED WARNING and CONTRAINDICATIONS. </p>
</b>

<p>Because of the known human teratogenicity of thalidomide, thalidomide is
contraindicated in women who are or may become pregnant and who are not using the two
required types of birth control or who are not continually abstaining from reproductive
heterosexual sexual intercourse. If thalidomide is taken during pregnancy, it can cause
severe birth defects or death to an unborn baby. Thalidomide should never be used by women
who are pregnant or who could become pregnant while taking<b> </b>the drug. Even a single
dose [1 capsule (50 mg)] taken by a pregnant woman can cause birth defects. If pregnancy
does occur during treatment, the drug should be immediately discontinued. Under these
conditions, the patient should be referred to an obstetrician / gynecologist experienced
in reproductive toxicity for further evaluation and counselling. Any suspected fetal
exposure to THALOMID (thalidomide) must be reported to the FDA <i>via</i> the MedWatch
program at 1-800-FDA-1088 and also to Celgene Corporation.</p>

<p>Animal studies to characterize the effects of thalidomide on late stage pregnancy have
not been conducted<b>.</p>

<p>Use in Nursing Mothers</p>
</b>

<p>It is not known whether thalidomide is excreted in human milk. Because many drugs are
excreted in human milk and because of the potential for serious adverse reactions in
nursing infants from thalidomide, a decision should be made whether to discontinue nursing
or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<b>

<p>Pediatric Use</p>
</b>

<p>Safety and effectiveness in pediatric patients below the age of 12 years have not been
established.</p>
<b>

<p>Geriatric Use</p>
</b>

<p>No systematic studies in geriatric patients have been conducted. Thalidomide has been
used in clinical trials in patients up to 90 years of age. Adverse events in patients over
the age of 65 years did not appear to differ in kind from those reported for younger
individuals.</p>
<font SIZE="2">

<p>&nbsp;</p>
</font><b>

<p>ADVERSE REACTIONS</p>
</b>

<p>The most serious toxicity associated with thalidomide is its documented human
teratogenicity. (See <b>BOXED WARNINGS</b> and <b>CONTRAINDICATIONS</b>) The risk of
severe birth defects, primarily phocomelia or death to the fetus, is extremely high during
the critical period of pregnancy. The critical period is estimated, depending on the
source of information, to range from 35 to 50 days after the last menstrual period. The
risk of other potentially severe birth defects outside this critical period is unknown,
but may be significant. Based on present knowledge, thalidomide must not be used at any
time during pregnancy.</p>

<p>Thalidomide is associated with drowsiness / somnolence, peripheral neuropathy,
dizziness / orthostatic hypotension, neutropenia, and HIV viral load increase. (<b>See
WARNINGS.)</b> </p>

<p>Hypersensitivity to THALOMID (thalidomide) and bradycardia in patients treated with
thalidomide have been reported. (<b>See PRECAUTIONS.)</p>
</b>

<p>Somnolence, dizziness, and rash are the most commonly observed adverse events
associated with the use of thalidomide. Thalidomide has been studied in controlled and
uncontrolled clinical trials in patients with ENL and in people who are HIV-seropositive.
In addition, thalidomide has been administered investigationally for more than 20 years in
numerous indications. Adverse event profiles from these uses are summarized in the
sections that follow.</p>
<b>

<p>Other Adverse Events:</p>
</b>

<p>Due to the nature of the longitudinal data that form the basis of this product's safety
evaluation, no determination has been made of the causal relationship between the reported
adverse events listed below and thalidomide. These lists are of various adverse events
noted by investigators in patients to whom they had administered thalidomide under various
conditions. </p>
<b>

<p>Incidence in Controlled Clinical Trials </p>
</b>

<p>Table 4 lists treatment-emergent signs and symptoms that occurred in THALOMID-treated
patients in controlled clinical trials in ENL. Doses ranged from 50 to 300 mg/day. All
adverse events were mild to moderate in severity, and none resulted in discontinuation.
Table 4 also lists treatment-emergent adverse events that occurred in at least 3 of the
THALOMID-treated HIV-seropositive patients who participated in an 8-week, placebo
controlled clinical trial. Events that were more frequent in the placebo-treated group are
not included. (See <b>WARNINGS, PRECAUTIONS,</b> and <b>DRUG INTERACTIONS.</b>)</p>
<b>

<p ALIGN="CENTER">Table 4</p>

<p ALIGN="CENTER">Summary of Adverse Events (AEs)</p>

<p ALIGN="CENTER">Reported in Celgene-sponsored Controlled Clinical Trials</p>
</b>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="7" WIDTH="704">
  <tr>
    <td WIDTH="33%" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">All AEs Reported Reported</b></font></td>
    <td WIDTH="50%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">AEs Reported in
    HIV-seropositive Patients</b></font></td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="7" WIDTH="704">
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Body System/Adverse Event</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">in ENL Patients</b></font></td>
    <td WIDTH="35%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">Thalidomide</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">Placebo</b></font></td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="3" BORDERCOLOR="#000000" CELLPADDING="7" WIDTH="704">
  <tr>
    <td WIDTH="33%" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">50 to 300 mg/day</p>
    <p ALIGN="CENTER">(N=24)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">100 mg/day</p>
    <p ALIGN="CENTER">(N=36)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">200 mg/day</p>
    <p ALIGN="CENTER">(N=32)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">(N=35)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Body as a Whole</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">16 (66.7%)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">18 (50.0%)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">19 (59.4%)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">13 (37.1%)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Abdominal pain</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.8%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (3.1%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.4%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Accidental injury</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.6%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.9%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Asthenia</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (8.3%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.6%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">7 (21.9%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.9%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Back pain</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.6%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Chills</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.4%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Facial edema</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Fever</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">7 (19.4%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">7 (21.9%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (17.1%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Headache</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (12.5%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (16.7%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (18.7%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.4%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Infection</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.3%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (6.3%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.9%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Malaise</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (8.3%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Neck pain</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Neck rigidity</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Pain</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (8.3%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (3.1%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Digestive System</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">5 (20.8%)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">16 (44.4%)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">16 (50.0%)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">15 (42.9%)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Anorexia</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.8%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Constipation</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.8%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Diarrhea</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.1%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (18.7%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (17.1%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Dry mouth</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.3%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Flatulence</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.3%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Liver function tests multiple abnormalities</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Nausea</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (12.5%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.9%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Oral moniliasis</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.1%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (6.3%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Tooth pain</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Hemic and Lymphatic</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">0</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">8 (22.2%)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">13 (40.6%)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">10 (28.6%)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Anemia</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.6%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (12.5%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.6%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Leukopenia</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (16.7%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">8 (25.0%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.6%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Lymphadenopathy</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.6%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (12.5%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.6%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Metabolic and Endocrine Disorders</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">1 (4.2%)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">8 (22.2%)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">12 (37.5%)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">8 (22.9%)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Edema peripheral</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.3%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (3.1%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Hyperlipemia</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.6%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.9%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">SGOT increased</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.8%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (12.5%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Nervous System</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">13 (54.2%)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">19 (52.8%)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">18 (56.3%)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">12 (34.3%)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Agitation</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Dizziness</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">7 (19.4%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (18.7%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Insomnia</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Nervousness</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.8%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Neuropathy</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.3%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Paresthesia</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.6%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">5 (15.6%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.4%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Somnolence</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">9 (37.5%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">13 (36.1%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">12 (37.5%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.4%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Tremor</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Vertigo</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (8.3%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Respiratory System</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">3 (12.5%)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">9 (25.0%)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">6 (18.7%)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">9 (25.7%)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Pharyngitis</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.3%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (6.3%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Rhinitis</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.4%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Sinusitis</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.3%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (3.1%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Skin and Appendages</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">10 (41.7%)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">17 (47.2%)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">18 (56.3%)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">19 (54.3%)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Acne</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.1%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (3.1%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Dermatitis fungal</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.6%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (9.4%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Nail disorder</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (3.1%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Pruritus</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (8.3%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.8%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (6.3%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Rash</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">5 (20.8%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">9 (25.0%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">8 (25.0%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">11 (31.4%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Rash maculo-papular</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (4.2%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (16.7%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">6 (18.7%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Sweating</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (12.5%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.4%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1"><b>Urogenital System</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">2 (8.3%)</b></font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">6 (16.7%)</b></font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">2 (6.3%)</b></font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><b><p ALIGN="CENTER">4 (11.4%)</b></font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Albuminuria</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">3 (8.3%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (3.1%)</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (5.7%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Hematuria</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">4 (11.1%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.9%)</font></td>
  </tr>
  <tr>
    <td WIDTH="33%" VALIGN="TOP"><font SIZE="1">Impotence</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">2 (8.3%)</font></td>
    <td WIDTH="18%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">1 (2.8%)</font></td>
    <td WIDTH="17%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="1"><p ALIGN="CENTER">0</font></td>
  </tr>
</table>
<b>

<p>Other Adverse Events Observed in ENL Patients</p>
</b>

<p>Thalidomide in doses up to 400 mg/day has been administered investigationally in the
United States over a 19-year period in 1465 patients with ENL. The published literature
describes the treatment of an additional 1678 patients. To provide a meaningful estimate
of the proportion of the individuals having adverse events, similar types of events were
grouped into a smaller number of standardized categories using a modified COSTART
dictionary / terminology. These categories are used in the listing below. All reported
events are included except those already listed in the previous table. Due to the fact
that these data were collected from uncontrolled studies, the incidence rate cannot be
determined. As mentioned previously, <b>no causal relationship between thalidomide and
these events can be conclusively determined at this time</b>. These are reports of all
adverse events noted by investigators in patients to whom they had administered
thalidomide. </p>
<i><b>

<p>Body as a Whole: </b></i>Abdomen enlarged, fever, photosensitivity, upper extremity
pain.</p>
<b><i>

<p>Cardiovascular System:</i> </b>Bradycardia, hypertension, hypotension, peripheral
vascular disorder, tachycardia.</p>
<b><i>

<p>Digestive System: </i></b>Anorexia, appetite increase/weight gain, dry mouth,
dyspepsia,<b> </b>enlarged liver, eructation, flatulence, increased liver function tests,
intestinal obstruction, vomiting.</p>
<i><b>

<p>Hemic and Lymphatic: </b></i>ESR decrease, eosinophilia, granulocytopenia, hypochromic
anemia, leukemia, leukocytosis, leukopenia, MCV elevated, RBC abnormal, spleen palpable,
thrombocytopenia.</p>
<b><i>

<p>Metabolic and Endocrine:</i> </b>ADH inappropriate, alkaline phosphatase, amyloidosis,
bilirubinemia, BUN increased, creatinine increased, cyanosis, diabetes, edema, electrolyte
abnormalities, hyperglycemia, hyperkalemia, hyperuricemia, hypocalcemia, hypoproteinemia,
LDH increased, phosphorus decreased, SGPT increased.</p>
<i><b>

<p>Muscular Skeletal: </b></i>Arthritis, bone tenderness, hypertonia, joint disorder, leg
cramps, myalgia, myasthenia, periosteal disorder.</p>
<i><b>

<p>Nervous System:</b> </i>Abnormal thinking, agitation, amnesia, anxiety, causalgia,
circumoral paresthesia, confusion, depression, euphoria, hyperesthesia, insomnia,
nervousness, neuralgia, neuritis, neuropathy, paresthesia, peripheral neuritis, psychosis,
vasodilation.</p>
<b><i>

<p>Respiratory System:</i> </b>Cough, emphysema, epistaxis, pulmonary embolus, rales,
upper respiratory infection, voice alteration.</p>
<b><i>

<p>Skin and Appendages:</i> </b>Acne, alopecia, dry skin, eczematous rash, exfoliative
dermatitis, ichthyosis, perifollicular thickening, skin necrosis, seborrhea, sweating,
urticaria, vesiculobullous rash.</p>
<b><i>

<p>Special Senses:</i> </b>Amblyopia, deafness, dry eye, eye pain, tinnitus.</p>
<b><i>

<p>Urogenital:</i> </b>Decreased creatinine clearance, hematuria, orchitis, proteinuria,
pyuria, urinary frequency.</p>
<b>

<p>Other Adverse Events Observed in HIV-seropositive Patients</p>
</b>

<p>In addition to controlled clinical trials, THALOMID has been used in uncontrolled
studies in 145 patients. Less frequent adverse events that have been reported in these
HIV-seropositive patients treated with THALOMID were grouped into a smaller number of
standardized categories using modified COSTART dictionary / terminology and these
categories are used in the listing below. Adverse events that have already been included
in the tables and narrative above, that are too general to be informative.</p>
<i><b>

<p>Body as a Whole:</b></i> Ascites, AIDS, allergic reaction, cellulitis, chest pain,
chills and fever, cyst, decreased CD4 count, facial edema, flu syndrome, hernia, hormone
level altered, moniliasis, photosensitivity reaction, sarcoma, sepsis, viral infection. </p>
<i><b>

<p>Cardiovascular System:</b></i> Angina pectoris, arrhythmia, atrial fibrillation,
bradycardia, cerebral ischemia, cerebrovascular accident, congestive heart failure, deep
thrombophlebitis, heart arrest, heart failure, hypertension, hypotension, murmur,
myocardial infarct, palpitation, pericarditis, peripheral vascular disorder, postural
hypotension, syncope, tachycardia, thrombophlebitis, thrombosis.</p>
<i><b>

<p>Digestive System:</b></i> Cholangitis, cholestatic jaundice, colitis, dyspepsia,
dysphagia, esophagitis, gastroenteritis, gastrointestinal disorder, gastrointestinal
hemorrhage, gum disorder, hepatitis, pancreatitis, parotid gland enlargement,
periodontitis, stomatitis, tongue discoloration, tooth disorder.</p>
<i><b>

<p>Hemic</b> <b>and Lymphatic</b>:</i> Aplastic anemia, macrocytic anemia, megaloblastic
anemia, microcytic anemia.</p>
<i><b>

<p>Metabolic and Endocrine</b>:</i> Avitaminosis, bilirubinemia, dehydration,
hypercholesteremia, hyperlipemia, increased alkaline phosphatase, increased lipase,
increased serum creatinine, peripheral edema.</p>
<b><i>

<p>Muscular Skeletal:</i> </b>Myalgia, myasthenia.</p>
<i><b>

<p>Nervous System:</b></i> Abnormal gait, ataxia, decreased libido, decreased reflexes,
dementia, dysesthesia, dyskinesia, emotional lability, hostility, hypalgesia,
hyperkinesia, incoordination, meningitis, neurologic disorder, tremor, vertigo.</p>
<i><b>

<p>Respiratory System:</b></i> Apnea, bronchitis, lung disorder, lung edema, pneumonia
(including <i>Pneumocystis carinii</i> pneumonia), rhinitis. </p>
<i><b>

<p>Skin and Appendages:</b> </i>Angioedema, benign skin neoplasm, eczema, herpes simplex,
incomplete Stevens-Johnson syndrome, nail disorder, pruritus, psoriasis, skin
discoloration, skin disorder.</p>
<i><b>

<p>Special Senses:</b></i> Conjunctivitis, eye disorder, lacrimation disorder, retinitis,
taste perversion.</p>
<b>

<p>Other Adverse Events in the Published Literature or Reported from Other Sources</p>
</b>

<p>The following additional events have been identified either in the published literature
or from spontaneous reports from other sources: acute renal failure, amenorrhea, aphthous
stomatitis, bile duct obstruction, carpal tunnel, chronic myelogenous leukemia, diplopia,
dysesthesia, dyspnea, enuresis, erythema nodosum, erythroleukemia, foot drop,
galactorrhea, gynecomastia, hangover effect, hypomagnesemia, hypothyroidism, lymphedema,
lymphopenia, metrorrhagia, migraine, myxedema, nodular sclerosing Hodgkin<font
face="WP TypographicSymbols">'</font>s disease, nystagmus, oliguria, pancytopenia,
petechiae, purpura, Raynaud<font face="WP TypographicSymbols">'</font>s syndrome, stomach
ulcer, and suicide attempt.</p>

<p>&nbsp;</p>
<b>

<p>DRUG ABUSE AND DEPENDENCE</p>
</b>

<p>Physical and psychological dependence has not been reported in patients taking
thalidomide.</p>

<p>However, as with other tranquilizers / hypnotics, thalidomide too has been reported to
create in patients habituation to its soporific effects.</p>

<p>&nbsp;</p>
<b>

<p>OVERDOSAGE</p>
</b>

<p>There have been three cases of overdose reported, all attempted suicides. There have
been no reported fatalities in doses of up to 14.4 grams, and all patients recovered
without reported sequelae.</p>

<p>&nbsp;</p>
<b>

<p>DOSAGE AND ADMINISTRATION</p>

<p>THALOMID MUST ONLY BE ADMINISTERED IN COMPLIANCE WITH ALL OF THE TERMS OUTLINED IN THE
S.T.E.P.S. PROGRAM. THALOMID MAY ONLY BE PRESCRIBED BY PRESCRIBERS REGISTERED WITH THE
S.T.E.P.S. PROGRAM AND MAY ONLY BE DISPENSED BY PHARMACISTS REGISTERED WITH THE S.T.E.P.S.
PROGRAM.</p>

<p>Drug prescribing to women of childbearing potential should be contingent upon initial
and continued confirmed negative results of pregnancy testing.</p>
</b>

<p>For an episode of cutaneous ENL, THALOMID dosing should be initiated at 100 to 300
mg/day, administered once daily with water, preferably at bedtime and at least 1 hour
after the evening meal. Patients weighing less than 50 kilograms should be started at the
low end of the dose range.</p>

<p>In patients with a severe cutaneous ENL reaction, or in those who have previously
required higher doses to control the reaction, THALOMID dosing may be initiated at higher
doses up to 400 mg/day once daily at bedtime or in divided doses with water, at least 1
hour after meals. </p>

<p>In patients with moderate to severe neuritis associated with a severe ENL reaction,
corticosteroids may be started concomitantly with THALOMID. Steroid usage can be tapered
and discontinued when the neuritis has ameliorated.</p>

<p>Dosing with THALOMID should usually continue until signs and symptoms of active
reaction have subsided, usually a period of at least 2 weeks. Patients may then be tapered
off medication in 50 mg decrements every 2 to 4 weeks. </p>

<p>Patients who have a documented history of requiring prolonged maintenance treatment to
prevent the recurrence of cutaneous ENL or who flare during tapering, should be maintained
on the minimum dose necessary to control the reaction. Tapering off medication should be
attempted every 3 to 6 months, in decrements of 50 mg every 2 to 4 weeks.</p>
<b>

<p>&nbsp;</p>

<p>HOW SUPPLIED</p>

<p>(THIS PRODUCT IS ONLY SUPPLIED TO PHARMACISTS REGISTERED WITH THE S.T.E.P.S. PROGRAM -
See BOXED WARNINGS.)</p>
</b>

<p>THALOMID (thalidomide) is supplied in hard gelatin, 50 mg capsules [white opaque],
imprinted &quot;Celgene&quot; with a &quot;do not get pregnant&quot; logo. Boxes
containing six prescription packs of 14 capsules each (84 capsules total).</p>

<p>NDC Number(s)</p>

<p>59572-105-02</p>
<b>

<p>STORAGE AND DISPENSING</p>

<p>PHARMACISTS NOTE: 

<dir>
  <p>DRUG MUST ONLY BE DISPENSED IN NO MORE THAN A 1-MONTH SUPPLY AND ONLY ON PRESENTATION
  OF A NEW PRESCRIPTION WRITTEN WITHIN THE PREVIOUS 14 DAYS. SPECIFIC INFORMED CONSENT (copy
  attached as part of this package insert) AND COMPLIANCE WITH THE MANDATORY PATIENT
  REGISTRY AND SURVEY ARE REQUIRED FOR ALL PATIENTS (MALE AND FEMALE) PRIOR TO DISPENSING BY
  THE PHARMACIST. </p>
  </b>
</dir>

<p>This drug must not be repackaged.</p>

<p>Store at 59 to 86<sup>0</sup>F; 15 to 30<sup>0</sup>C. Protect from light.</p>

<p>Rx only and only able to be prescribed and dispensed under the terms of the S.T.E.P.S.
Restricted Distribution Program</p>

<p>Manufactured by Celgene Corporation</p>

<p>7 Powder Horn Drive</p>

<p>Warren, New Jersey 07059</p>
<b>

<p>Important Information and Warnings For All Patients Taking THALOMID<sup>TM</sup>
(thalidomide)</p>
</b>

<table BORDER="1" CELLSPACING="1" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="689">
  <tr>
    <td VALIGN="TOP"><b>&nbsp;<p>WARNING: SERIOUS HUMAN BIRTH DEFECTS</p>
    <p>IF THALIDOMIDE IS TAKEN DURING PREGNANCY, IT CAN CAUSE SEVERE BIRTH DEFECTS OR DEATH TO
    AN UNBORN BABY. THALIDOMIDE SHOULD NEVER BE USED BY WOMEN WHO ARE PREGNANT OR WHO COULD
    BECOME PREGNANT WHILE TAKING THE DRUG. EVEN A SINGLE DOSE [1 CAPSULE (50 mg)] TAKEN BY A
    PREGNANT WOMAN CAN CAUSE SEVERE BIRTH DEFECTS.</b></td>
  </tr>
</table>
<font SIZE="2">

<p>&nbsp;</p>
</font>

<table BORDER="1" CELLSPACING="1" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="689">
  <tr>
    <td VALIGN="TOP"><font SIZE="2"><b>CONSENT FOR WOMEN:</b></font></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 1. I understand that I must not take THALOMID<sup>TM</sup>
            (thalidomide) if I am pregnant, breast-feeding a baby, or able to get pregnant and not
            using the required two methods of birth control.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 2. I understand that severe birth defects can occur with the
            use of THALOMID<sup>TM</sup> (thalidomide). I have been warned by my doctor that my unborn
            baby will almost certainly have serious birth defects or may even die if I am pregnant or
            become pregnant while taking THALOMID<sup>TM</sup> (thalidomide).</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 3. I understand that if I am able to become pregnant, I must
            use at least one highly effective method and one additional effective method of birth
            control (contraception) AT THE SAME TIME:</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2"><b>At least one highly effective method One additional
    effective method</b><p>IUD </font><u><b>AND</b></u><font SIZE="2"> Latex condom</p>
    <p>Hormonal (Birth control pills) Diaphragm</p>
    <p>Tubal ligation Cervical cap</p>
    <p>Partner<font face="WP TypographicSymbols">'</font>s vasectomy</font></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>These birth control methods must be used for at least 4 weeks before
            starting THALOMID therapy, all during THALOMID therapy, and for at least 4 weeks after
            THALOMID therapy has stopped. I must use these methods even if I am infertile, unless I
            have has a hysterectomy or because I have been post-menopausal for at least 24 months
            (been through the changes of life). The only exception is if I <u>completely avoid
            heterosexual sexual intercourse</u>. If a hormonal (birth control pills) or IUD method is
            not medically possible for me, I may use another highly effective method or two barrier
            methods AT THE SAME TIME.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 4. I know that I must have a pregnancy test done by my doctor
            within the 24 hours prior to starting THALOMID therapy, then <u>every week</u> during the
            first 4 weeks of THALOMID therapy. I will then have a pregnancy test <u>every 4 weeks</u>
            if I have regular menstrual cycles, or <u>every 2 weeks</u> if my cycles are irregular
            while I am taking THALOMID.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 5. I know that I must immediately stop taking THALOMID<sup>TM</sup>
            and inform my doctor if I become pregnant while taking the drug; if I miss my menstrual
            period, or experience unusual menstrual bleeding; stop using birth control; or think, FOR
            ANY REASON, that I may be pregnant. If my doctor is not available, I can call
            1-888-668-2528 for information on emergency contraception.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 6. I am not now pregnant, nor will I try to become pregnant for
            at least 4 weeks after I have completely finished taking THALOMID<sup>TM</sup>.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 7. I understand that THALOMID<sup>TM</sup> will be prescribed
            ONLY for me. I must NOT share it with ANYONE, even someone who has symptoms similar to
            mine. It must be kept out of the reach of children and should never be given to women who
            are able to have children.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 8. I have read the THALOMID<sup>TM</sup> patient brochure
            and/or viewed the videotape, &quot;Important Information for Men and Women Taking THALOMID<sup>TM</sup>
            (thalidomide)&quot;. I understand the contents, including other possible health problems
            from THALOMID<sup>TM</sup>, so-called &quot;side effects&quot;. I know that I cannot
            donate blood while taking THALOMID<sup>TM</sup>.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 9. My doctor has answered any questions I have asked.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 10. I understand that I must participate in a survey and
            patient registry while I am on THALOMID<sup>TM</sup> , which will require completing
            additional forms.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
</table>

<table BORDER="1" CELLSPACING="1" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="689">
  <tr>
    <td VALIGN="TOP"><font SIZE="2"><b>CONSENT FOR MEN:</b></font></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 1. I understand that I must not take THALOMID<sup>TM</sup> if I
            cannot avoid unprotected sex with a woman , even if I have had a successful vasectomy.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 2. I understand that severe birth defects or death to an unborn
            baby have occurred when women took thalidomide during pregnancy.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 3. I have been told by my doctor that I must NEVER have
            unprotected sex with a woman because it is not known if the drug is present in semen or
            sperm. My doctor has explained that I must either completely avoid heterosexual sexual
            intercourse or I must use a latex condom EVERY TIME I have sexual intercourse with a
            female partner while I am taking THALOMID<sup>TM</sup> - and for 4 weeks after I stop
            taking the drug, even if I have had a successful vasectomy.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 4. I also know that I must inform my doctor if I have had
            unprotected sex with a woman; or if I think, FOR ANY REASON, that my sexual partner may be
            pregnant. If my doctor is not available, I can call 1-888-668-2528 for information on
            emergency contraception.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 5. I understand that THALOMID<sup>TM</sup> will be prescribed
            ONLY for me. I must NOT share it with ANYONE, even someone who has symptoms similar to
            mine. It must be kept out of the reach of children and should never be given to women who
            are able to have children.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 6. I have read the THALOMID<sup>TM</sup> patient brochure
            and/or viewed the videotape, &quot;Important Information for Men and Women Taking THALOMID<sup>TM</sup>
            (thalidomide)&quot;. I understand the contents, including other possible health problems
            from THALOMID<sup>TM</sup> (thalidomide), so-called &quot;side effects&quot;. I know that
            I cannot donate blood or semen while taking THALOMID<sup>TM</sup> (thalidomide).</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 7. My doctor has answered any questions I have asked.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
  <tr>
    <td VALIGN="TOP"><dir>
      <dir>
        <dir>
          <dir>
            <font SIZE="2"><p>INIT:___ 8. I understand that I must participate in a survey and patient
            registry while I am on THALOMID<sup>TM</sup>, which will require completing additional
            forms.</font></p>
          </dir>
        </dir>
      </dir>
    </dir>
    </td>
  </tr>
</table>

<p>&nbsp;</p>

<table BORDER="1" CELLSPACING="1" BORDERCOLOR="#000000" CELLPADDING="8" WIDTH="689">
  <tr>
    <td VALIGN="TOP"><font SIZE="2"><b>Authorization:</b></font></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">This information has been read aloud to me in the language
    of my choice. I understand that if I do not follow all of my doctor<font
    face="WP TypographicSymbols">'</font>s instructions, I will not be able to receive
    THALOMID<sup>TM</sup> . I now authorize my doctor to begin my treatment with THALOMID<sup>TM</sup>
    .</font></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">_______________________________________________________________________________</font></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">Patient Name (please print) Social Security No. Date of
    Birth<p>(Only last six digits required) (mo./day/yr.)</font></td>
  </tr>
  <tr>
    <td VALIGN="TOP">________________________________________________________</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">Patient, Parent / Guardian Signature Date (mo./day/yr.)</font></td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">I have fully explained to the patient the nature, purpose,
    and risks of the treatment described above, especially the risks to women of childbearing
    potential. I have asked the patient if she/he has any questions regarding her/his
    treatment with THALOMID<sup>TM</sup> and have answered those questions to the best of my
    ability. I will ensure that the appropriate components of the patient consent form are
    completed. In addition, I will comply with all of my obligations and responsibilities as a
    prescriber registered under the S.T.E.P.S. restricted distribution program.</font></td>
  </tr>
  <tr>
    <td VALIGN="TOP">________________________________________________________</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">Physician Name (please print) DEA No.</font><p>________________________________________________________</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">Physician Signature Date (mo./day/yr.)</font></td>
  </tr>
</table>
<font SIZE="2">

<p>&nbsp;</p>
</font><b>

<p>REFERENCES</b> 

<dir>
  <dir>
    <p>1. Manson JM. 1986. Teratogenicity. Cassarett and Doull<font
    face="WP TypographicSymbols">'</font>s Toxicology: The Basic Science of Poisons. Third
    Edition. Pages 195-220. New York: MacMillan Publishing Co.</p>
    <p>2. Smithels RW and Newman CG. 1992. J. Med. Genet. 29(10):716-723.</p>
    <p>3. Sampaio EP, Sarno EN, Galilly R, <i>et al</i>. 1992. J. Exp. Med. 168:408-414.</p>
    <p>4. Sarno EN, Grau GE, Vieira LM, <i>et al</i>. 1991. Clin. Exp. Immunol. 84:103-108.</p>
    <p>5. Sampaio EP, Moreira AL, Sarno EN, <i>et al</i>. 1992. J. Exp. Med. 175:1729-1737.</p>
    <p>6. Nogueira AC, Neubert R, Helge H, <i>et al</i>. 1994. Life Sciences. 55(2):77-92.</p>
    <p>7. Jacobson JM, Greenspan JS, Spritzler J, <i>et al</i>. 1997. New Eng. J. Med.
    336(21):1487-1493.</p>
    <p>8. Schumaker H, Smith RL, and Williams RT. 1965. Br. J. Pharmacol. 25:324-337.</p>
    <p>9. Iyer CGS, Languillon J, Ramanujam K, <i>et al</i>. 1971. Bull. WHO. 45:719-732.</p>
    <p>10. Sheskin J and Convit J. 1969. Intl. J. Leprosy. 37:135-146.</p>
    <p>11. Waters MFR. 1971. Lepr. Rev. 42:26-42.</p>
    <p>12. Unpublished data, on file at Celgene.</p>
  </dir>
</dir>
</body>
</html>
